Jupiter Neurosciences (NASDAQ:JUNS) Shares Up 18.2% – Should You Buy?

Shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) were up 18.2% on Tuesday. The company traded as high as $3.18 and last traded at $2.86. Approximately 922,991 shares traded hands during trading, an increase of 1,657% from the average session volume of 52,527 shares. The stock had previously closed at $2.42.

Analyst Ratings Changes

A number of equities analysts have recently commented on JUNS shares. Wall Street Zen upgraded shares of Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a report on Sunday, August 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Monday, September 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Jupiter Neurosciences Stock Performance

The stock’s fifty day moving average is $4.12 and its two-hundred day moving average is $15.30. The company has a market cap of $2.52 million, a price-to-earnings ratio of -0.14 and a beta of 1.90.

Jupiter Neurosciences (NASDAQ:JUNS) last released its quarterly earnings results on Friday, August 14th. The company reported ($5.06) EPS for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.40 million.

Institutional Investors Weigh In On Jupiter Neurosciences

An institutional investor recently raised its stake in Jupiter Neurosciences stock. Vestor Capital LLC raised its holdings in shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) by 144,607.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 970,985 shares of the company’s stock after purchasing an additional 970,314 shares during the quarter. Vestor Capital LLC owned approximately 2.68% of Jupiter Neurosciences worth $365,000 as of its most recent filing with the Securities & Exchange Commission.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neuroinflammatory disorders. The company’s research centers on reducing inflammation in the brain and central nervous system, a process implicated in conditions such as stroke, traumatic brain injury and neurodegenerative diseases.

Jupiter Neurosciences’ lead product candidate is JNS101, an orally administered, brain-penetrant formulation based on curcumin, a naturally occurring compound with potential anti-inflammatory and neuroprotective properties.